Vaping cannabidiol (CBD), a compound found in marijuana, leads to more severe lung damage than vaping nicotine, according to a study out of Roswell Park Comprehensive Cancer Center. Until now, research on the health effects of vaping, or using e-cigarettes, has focused almost exclusively on vaping nicotine as opposed to CBD. Previous research has documented the effects of smoking cannabis, but the effects of vaping cannabinoids such as CBD were not previously known.
The National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading United States cancer centers—announces a new collaboration with the Institute of Hematology and Transfusion Medicine in Poland (IHIT), and the Alliance For Innovation—Polish-American Foundation (AFI).
The mural, designed in collaboration with members of organizations in the surrounding urban community, is one part of the The University of Kansas Cancer Center’s broader campaign to increase the participation of minority and underserved populations in clinical trials.
A Yale-led study examines the potential environmental benefits of more carefully selecting patients for prostate biopsy in a way that can also spare low-yield and potentially harmful procedures
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments include a new understanding of how HPV drives cancer development, a combination therapy to overcome treatment resistance in mantle cell lymphoma, novel insights into memory T cell formation and potential therapeutic strategies for brain cancers, improved survival outcomes for metastatic colorectal cancer, targeting myeloperoxidase to improve immunotherapy responses in melanoma, and preclinical results of a combination therapy that could effectively treat a subset of acute myeloid leukemia.
Patients with early-stage estrogen receptor-positive breast cancer who live in low-income neighborhoods are likelier to have more-aggressive tumors and significantly lower overall survival (OS) than those in higher-income neighborhoods, according to research led by Roswell Park Comprehensive Cancer Center. The study, “Association of neighborhood-level household income with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer,” appears today in JAMA Network Open.
This study shows vaccination against COVID-19 is an essential strategy to improve outcomes in this high-risk population. The results support guidelines that patients with cancer should receive at least 3 COVID-19 vaccine doses.
20221027104337.jpg&width=400&height=400)
Early diagnosis of uterine cancer is known to improve a patient’s chances for survival, but previous research has found that Black patients are less likely to receive early diagnoses than people of other racial and ethnic groups. A new analysis by Yale researchers provides insights into why that is: They found that Black patients were more likely than their white counterparts to experience testing delays or to not receive recommended tests at all.
The University of Texas MD Anderson Cancer Center today was awarded 15 grants totaling $19.38 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of cancer research projects across the institution.
New research in the February 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network illustrates how the use of an algorithm to calculate a patient-reported symptom complexity score can help oncologists identify patients who are at increased risk for unplanned visits to the emergency department (ED), creating the potential for additional proactive care, and the reduction of healthcare costs.
MD Anderson and Xilis announced a strategic collaboration to deploy Xilis' proprietary MicroOrganoSphere technology in support of preclinical research to accelerate the development of novel cancer therapies.
MD Anderson and Replay announced the launch of Syena, a new oncology-focused product company pioneering T cell receptor (TCR) natural killer (NK) cell therapies.
New UC Davis Health research confirms that pediatric critical care telemedicine consults with clinicians in rural and community emergency departments result in fewer hospital transfers.
Researchers at The University of Texas MD Anderson Cancer Center have identified CD70 as being highly expressed on drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer (NSCLC), highlighting a novel therapeutic target that could be used to eliminate resistant cells remaining after treatment with commonly used EGFR tyrosine kinase inhibitors (TKIs). The study published today in Cancer Cell.
Moffitt Cancer Center has named three new research leaders who will help elevate our science and innovative discoveries.
In a new study published in the journal Cancer Immunology Research, our researchers, led by Amer A. Beg, Ph.D., show how stimulating dendritic cells through the CD40 and interferon β (IFNβ) pathways produces strong T cell activity against tumors and works in conjunction with immune checkpoint inhibitors to produce even stronger responses. The article also shares promising early results from a phase 1 clinical study of an oncolytic virus (MEM-288) that activates these pathways in patients with non-small cell lung cancer.
A team of researchers from Yale and the University of Connecticut (UConn) has developed a nanoparticle-based treatment that targets multiple culprits in glioblastoma, a particularly aggressive and deadly form of brain cancer.
In a new study, researchers at Dana-Farber Cancer Institute used cryo-electron microscopy to reveal for the first time how one IAP, a protein called BIRC6, operates at a molecular level to inhibit programmed cell death.
Age-based heuristics can lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new analysis of more than 500,000 patient records. Radiation therapy often is given after breast-conserving surgery to help prevent a patient’s cancer from returning.
UC Davis Comprehensive Cancer Center researchers are part of a large-scale research study to test a new drug therapy to treat pancreatic cancer.
Risk model-based lung cancer screening strategies, which select individuals based on personal risk, are more cost effective than current recommendations based solely on age and smoking history, according to a study led by the Cancer Intervention and Surveillance Modeling Network (CISNET) Lung Working Group, which includes researchers from The University of Texas MD Anderson Cancer Center.
A study from researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Cell Biology, details a previously unexplained type of cell death called disulfidptosis that could open the door for novel cancer therapeutic strategies.
An ongoing pilot project aims to evaluate the feasibility of implementing the Health Equity Report Card (HERC) as a tool for improving the quality and equity of cancer care and continues the Elevating Cancer Equity collaboration from the National Comprehensive Cancer Network (NCCN), American Cancer Society Cancer Action Network (ACS CAN), and National Minority Quality Forum (NMQF)--highlighted on World Cancer Day.
The University of Texas MD Anderson Cancer Center today announced the expansion of its global oncology efforts through a new agreement with the Ministry of Health of the Republic of Indonesia. This relationship builds on MD Anderson’s efforts to share best practices in cancer education, prevention, research and treatment to reduce the burden of cancer worldwide.
Researchers at Moffitt Cancer Center are investigating new treatment approaches for this patient population. In a new article published in the International Journal of Radiation Oncology, Biology and Physics, our team of physicians, led by Daniel Oliver, M.D., and Stephen Rosenberg, M.D., shows that stereotactic body radiotherapy, or SBRT, is an effective treatment for patients with early stage lung neuroendocrine tumors.
As an association representing 108 of North America’s leading cancer centers, AACI has actively supported the president’s cancer efforts and stands ready to continue its collaboration with the Biden administration, the NCI, and others who are accelerating progress against cancer.
The second season of Unraveled: A Dana-Farber Cancer Institute podcast is now available with six new episodes telling stories of the science and scientists behind some of the most important cancer discoveries, diving deep into the lab.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
MD Anderson and Federation Bio announced a strategic collaboration to design and manufacture a synthetic microbial consortium with the goal of improving responses in immunotherapy-resistant cancers.
A new study by UC Davis MIND Institute researchers finds that changes in the IQ level of autistic youth may help predict their developmental path as adolescents.
Stephen Lai, M.D., Ph.D., Cullen Taniguchi, M.D, Ph.D., and Apostolia Tsimberidou, M.D., Ph.D. have been named fellows of the American Association for the Advancement of Science (AAAS) for their notable contributions to the field of cancer research. This distinction is one of the highest honors in the scientific research community
A new UC Davis study reveals the interaction between tumor microbiome and the immune system may be the secret to improving outcomes for sarcoma patients.
Despite their rarity, it’s important to know the signs and symptoms of bile duct and gallbladder cancers.
In an internationally conducted clinical trial lead by Dana-Farber involving patients with recurrent ovarian cancer that is resistant to platinum therapy, a novel conjugate therapy called mirvetuximab soravtansine resulted in substantially better responses than standard treatments. Mirvetuximab soravtansine was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in November 2022.
Moffitt Cancer Center, Weill Cornell Medicine and the University of North Carolina School of Medicine have received a $3.5 million, five-year grant from the National Cancer Institute (NCI) to improve screening and preventative treatment of cervical cancer for women living with HIV in low-resource countries.
The bottom line: before, during and after cancer treatment, heart health is critical. Andrew M. Evens, DO, MBA, MSc, associate director for Clinical Services at Rutgers Cancer Institute of New Jersey and medical director of the Oncology Service Line at RWJBarnabas Health, is a participating physician in the Cardio-Oncology Program at Rutgers Cancer Institute of New Jersey, the state’s leading cancer program, in partnership with RWJBarnabas Health, shares more on the topic.
Elisa V. Bandera, MD, PhD and Carolyn J. Heckman, PhD, co-leaders of the Cancer Prevention and Control Research Program at Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute (NCI)-Designated Comprehensive Cancer Center, together with RWJBarnabas Health, share their top tips for cancer prevention during National Cancer Prevention Month.
Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to results from the international Phase III MOMENTUM trial led by researchers at The University of Texas MD Anderson Cancer Center.
In a new study published by JAMA Network Open, Dr. Elisa Bandera, Dr. Nur Zeinomar from Rutgers Cancer Institute of New Jersey and colleagues found that a higher risk of mortality in Black breast cancer survivors is associated with a history of cigarette smoking along with regular alcohol consumption at the time of diagnosis.
This study provides a mechanism for rapidly identifying the protein kinase that is driving the abnormal behavior of individual cancers.
A combination of two next-generation immunotherapy drugs has shown promising clinical activity in treating patients with refractory metastatic colorectal cancer, a disease which has not previously responded well to immunotherapies, according to a Dana-Farber Cancer Institute researcher.
It is with great pleasure that we announce the appointment of Jedd Wolchok and Nicolas Killen to the Board of Directors of the Ludwig Institute for Cancer Research and the LICR Fund, which manages the assets of the Institute.
Moffitt Cancer Center researchers have developed a tool to determine how a new class of prostate cancer therapies called radionuclide therapy (RNT) impacts patient-reported outcomes with the goal of using this information to guide treatment and improve quality of care. Their findings have been published in The Journal of Nuclear Medicine.
MD Anderson announced licensing agreements with BostonGene and Tempus for the MD Anderson EGFR Classification, which organizes EGFR mutations into subgroups that may guide clinical decision-making.
National Comprehensive Cancer Network’s new Diversity, Equity, & Inclusion (DEI) Directors Forum is working together to improve diversity of clinical staff representation across nation’s leading academic cancer centers.
Rachel Pozzar, PhD, RN, a nurse scientist in the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, has been awarded the 2023 Oncology Nursing Society’s (ONS) Victoria Mock New Investigator Award.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
